CD8A and neoplasm: While some cancers are immunogenic enough to sustain anti-tumor CD8+ T cell responses in the tumor and periphery, one of the barriers to success with checkpoint inhibitor therapy is thought to be the absence of anti-tumor T cells to non-immunogenic tumors.